Andrea Corcoran - 31 Jan 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Financial Officer, Executive Vice President, Legal and Secretary
Signature
/s/ Andrea Corcoran
Issuer symbol
AVIR
Transactions as of
31 Jan 2026
Net transactions value
-$68,281
Form type
4
Filing time
03 Feb 2026, 19:46:35 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Corcoran Andrea Chief Financial Officer, Executive Vice President, Legal and Secretary 225 FRANKLIN STREET, SUITE 2100, BOSTON /s/ Andrea Corcoran 03 Feb 2026 0001296996

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +54,866 +7.6% 779,680 31 Jan 2026 Direct F1, F2
transaction AVIR Common Stock Tax liability $68,281 -16,104 -2.1% $4.24 763,576 31 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -44,366 -100% $0.000000 0 31 Jan 2026 Common Stock 44,366 Direct F1, F3
transaction AVIR Restricted Stock Units Options Exercise $0 -10,500 -100% $0.000000 0 31 Jan 2026 Common Stock 10,500 Direct F1, F4
transaction AVIR Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 31 Jan 2026 Common Stock 180,000 $4.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Includes 7,507 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
F3 The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F4 Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F5 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Remarks:

Chief Financial Officer, Executive Vice President, Legal and Secretary